Gut Bacteria and Cholesterol

Medically reviewed | Published: | Evidence level: 1A
Researchers are investigating how certain intestinal bacteria transform cholesterol into compounds that are less readily absorbed by the body. The findings could eventually support new cardiovascular treatments, but scientists have not yet established that microbiome products can reliably prevent heart attacks or replace cholesterol-lowering medicines.
📅 Published:
Reviewed by iMedic Medical Editorial Team
📄 Cardiovascular Health

Quick Facts

Research Focus
Microbial cholesterol metabolism
Key Microbes
Oscillibacter species
Clinical Status
Not a treatment yet

How Can Gut Bacteria Affect Cholesterol Levels?

Quick answer: Some intestinal bacteria can chemically transform cholesterol, potentially reducing how much remains available for absorption.

The gut microbiome contains microorganisms whose enzymes modify nutrients, medicines and substances produced by the human body. Research highlighted by the National Institutes of Health has identified bacterial pathways that convert cholesterol into related compounds, including coprostanol, which is absorbed less efficiently and is largely eliminated in stool.

Scientists have linked bacteria from the genus Oscillibacter with this cholesterol-processing activity. The relationship is biologically plausible, but an association between particular microbes and lower cholesterol does not prove that adding those microbes will improve cardiovascular outcomes. Diet, genetics, medications, liver function and the rest of the microbial community may all influence the effect.

Could Microbiome Research Lead to New Cholesterol Treatments?

Quick answer: Microbial enzymes may provide targets for future therapies, although no approved microbiome treatment currently replaces established cholesterol-lowering care.

Researchers could potentially use the newly characterized pathway in several ways: identifying bacterial enzymes as drug targets, developing carefully tested live biotherapeutic products or designing dietary interventions that support beneficial microbial activity. Such strategies would require controlled human trials demonstrating consistent effects, acceptable safety and meaningful reductions in cardiovascular events.

Developing a treatment is more complicated than identifying a promising bacterium. Microbes may behave differently across individuals, and introducing a strain does not guarantee that it will survive or produce the desired metabolites. Investigators must also examine unintended metabolic effects, interactions with medicines and risks for people with weakened immune systems.

Should People Change Their Cholesterol Care Based on These Findings?

Quick answer: No; patients should continue evidence-based treatment while microbiome-based approaches remain experimental.

People should not stop statins or other prescribed lipid-lowering medicines because of early microbiome research. Established care includes assessing overall cardiovascular risk, addressing tobacco exposure, maintaining regular physical activity, choosing a fiber-rich dietary pattern and using medication when clinically indicated.

A varied diet containing vegetables, fruits, legumes and whole grains can support general cardiovascular and digestive health, but commercial probiotics are not proven substitutes for cholesterol medication. Anyone concerned about cholesterol should discuss lipid testing and treatment decisions with a qualified healthcare professional rather than attempting unvalidated microbiome therapies.

Frequently Asked Questions

Some probiotic studies have reported modest changes in blood lipids, but results vary by strain and study design. No over-the-counter probiotic has been shown to replace statins or other guideline-directed cholesterol treatments.

Coprostanol is a product formed when certain gut microbes metabolize cholesterol. It is poorly absorbed compared with cholesterol and is commonly eliminated in feces.

Routine consumer microbiome testing is not currently recommended for diagnosing cardiovascular risk or selecting cholesterol treatment. Standard risk assessment relies on validated measures such as blood lipids, blood pressure, diabetes status, smoking history and clinical history.

References

  1. National Institutes of Health. Gut bacteria may reduce cholesterol and lower heart disease risk. NIH Research Matters.
  2. Cell. Research on gut microbial pathways involved in human cholesterol metabolism. 2024.
  3. Centers for Disease Control and Prevention. About Heart Disease.